Biomerica (BMRA) Competitors

$2.25 -0.09 (-3.85%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$2.24 -0.01 (-0.44%)

As of 03:59 AM Eastern

BMRA vs. BRNS, NEUP, TPST, SNSE, and KYNB

Should you buy Biomerica stock or one of its competitors? MarketBeat compares Biomerica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biomerica include Barinthus Biotherapeutics (BRNS), Neuphoria Therapeutics (NEUP), Tempest Therapeutics (TPST), Sensei Biotherapeutics (SNSE), and Kyntra Bio (KYNB). These companies are all part of the "pharmaceutical products" industry.

How does Biomerica compare to Barinthus Biotherapeutics?

Biomerica (NASDAQ:BMRA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Barinthus Biotherapeutics' average media sentiment score of 0.94 beat Biomerica's score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomerica	Neutral
Barinthus Biotherapeutics	Positive

Biomerica has higher earnings, but lower revenue than Barinthus Biotherapeutics. Biomerica is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A
Barinthus Biotherapeutics	$14.97M	1.74	-$66.43M	-$1.29	N/A

Biomerica has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.43, indicating that its share price is 143% less volatile than the broader market.

Biomerica currently has a consensus target price of $9.00, indicating a potential upside of 300.00%. Barinthus Biotherapeutics has a consensus target price of $4.00, indicating a potential upside of 526.47%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Barinthus Biotherapeutics' return on equity of -63.83% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Barinthus Biotherapeutics beats Biomerica on 11 of the 15 factors compared between the two stocks.

How does Biomerica compare to Neuphoria Therapeutics?

Neuphoria Therapeutics (NASDAQ:NEUP) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Neuphoria Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Neuphoria Therapeutics has higher earnings, but lower revenue than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuphoria Therapeutics	-$13.27K	-1,917.96	-$370K	-$11.06	N/A
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Neuphoria Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 344.92%. Biomerica has a consensus price target of $9.00, indicating a potential upside of 300.00%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Biomerica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Neuphoria Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Neuphoria Therapeutics' return on equity of -85.43% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-85.43%	-56.52%
Biomerica	-96.49%	-98.14%	-70.42%

In the previous week, Neuphoria Therapeutics had 4 more articles in the media than Biomerica. MarketBeat recorded 4 mentions for Neuphoria Therapeutics and 0 mentions for Biomerica. Neuphoria Therapeutics' average media sentiment score of 0.41 beat Biomerica's score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neuphoria Therapeutics	Neutral
Biomerica	Neutral

Summary

Neuphoria Therapeutics beats Biomerica on 11 of the 16 factors compared between the two stocks.

How does Biomerica compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Biomerica has higher revenue and earnings than Tempest Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A

In the previous week, Tempest Therapeutics had 5 more articles in the media than Biomerica. MarketBeat recorded 5 mentions for Tempest Therapeutics and 0 mentions for Biomerica. Biomerica's average media sentiment score of 0.00 beat Tempest Therapeutics' score of -1.00 indicating that Biomerica is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Negative
Biomerica	Neutral

Tempest Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Biomerica	-96.49%	-98.14%	-70.42%

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tempest Therapeutics has a beta of -1.75, indicating that its stock price is 275% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Biomerica has a consensus target price of $9.00, suggesting a potential upside of 300.00%. Given Biomerica's higher possible upside, analysts plainly believe Biomerica is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Biomerica beats Tempest Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Biomerica compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Sensei Biotherapeutics has a net margin of 0.00% compared to Biomerica's net margin of -96.49%. Biomerica's return on equity of -98.14% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-803.00%	-672.60%
Biomerica	-96.49%	-98.14%	-70.42%

Sensei Biotherapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the broader market. Comparatively, Biomerica has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 18.0% of Biomerica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 28 more articles in the media than Biomerica. MarketBeat recorded 28 mentions for Sensei Biotherapeutics and 0 mentions for Biomerica. Sensei Biotherapeutics' average media sentiment score of 0.08 beat Biomerica's score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
Biomerica	Neutral

Sensei Biotherapeutics presently has a consensus price target of $40.00, suggesting a potential upside of 100.90%. Biomerica has a consensus price target of $9.00, suggesting a potential upside of 300.00%. Given Biomerica's higher possible upside, analysts clearly believe Biomerica is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biomerica has higher revenue and earnings than Sensei Biotherapeutics. Biomerica is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A

Summary

Biomerica beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Biomerica compare to Kyntra Bio?

Biomerica (NASDAQ:BMRA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Kyntra Bio has higher revenue and earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.31M	1.31	-$4.97M	-$0.89	N/A
Kyntra Bio	$6.44M	4.30	$183.45M	$40.46	0.17

In the previous week, Kyntra Bio had 6 more articles in the media than Biomerica. MarketBeat recorded 6 mentions for Kyntra Bio and 0 mentions for Biomerica. Kyntra Bio's average media sentiment score of 0.67 beat Biomerica's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Biomerica	Neutral
Kyntra Bio	Positive

Kyntra Bio has a net margin of 2,199.13% compared to Biomerica's net margin of -96.49%. Kyntra Bio's return on equity of 0.00% beat Biomerica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Kyntra Bio	2,199.13%	N/A	-36.71%

22.3% of Biomerica shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 2.0% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Biomerica currently has a consensus price target of $9.00, suggesting a potential upside of 300.00%. Given Biomerica's higher probable upside, equities research analysts clearly believe Biomerica is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Biomerica has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Summary

Kyntra Bio beats Biomerica on 14 of the 16 factors compared between the two stocks.

Get Biomerica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRA vs. The Competition

Export

Metric	Biomerica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.23M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.31%
P/E Ratio	-2.53	17.22	20.63	25.23
Price / Sales	1.31	286.32	552.00	79.35
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	1.40	3.93	9.67	6.63
Net Income	-$4.97M	$74.99M	$3.56B	$335.59M
7 Day Performance	-1.36%	-4.47%	-1.65%	-1.20%
1 Month Performance	3.21%	-7.93%	-2.61%	-1.16%
1 Year Performance	-37.50%	29.34%	30.05%	28.10%

Biomerica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRA Biomerica	1.2576 of 5 stars	$2.25 -3.8%	$9.00 +300.0%	-38.2%	$7.23M	$5.31M	N/A	60
BRNS Barinthus Biotherapeutics	2.8204 of 5 stars	$0.70 +2.2%	$4.00 +471.4%	-32.4%	$27.98M	$14.97M	N/A	107	Gap Up
NEUP Neuphoria Therapeutics	2.5853 of 5 stars	$4.93 -4.6%	$21.00 +326.0%	-4.1%	$27.87M	$14.99M	N/A	N/A	Earnings Report Short Interest Increase
TPST Tempest Therapeutics	1.7606 of 5 stars	$1.92 -1.0%	N/A	-73.4%	$27.83M	N/A	N/A	20	Earnings Report Analyst Downgrade Short Interest Decrease
SNSE Sensei Biotherapeutics	2.5655 of 5 stars	$21.00 +1.3%	$40.00 +90.5%	+189.4%	$27.80M	N/A	N/A	40	News Coverage Earnings Report Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRA) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomerica (BMRA) Competitors

BMRA vs. BRNS, NEUP, TPST, SNSE, and KYNB

How does Biomerica compare to Barinthus Biotherapeutics?

Summary

How does Biomerica compare to Neuphoria Therapeutics?

Summary

How does Biomerica compare to Tempest Therapeutics?

Summary

How does Biomerica compare to Sensei Biotherapeutics?

Summary

How does Biomerica compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomerica (BMRA) Competitors

BMRA vs. BRNS, NEUP, TPST, SNSE, and KYNB

How does Biomerica compare to Barinthus Biotherapeutics?

Does the media prefer BMRA or BRNS?

Which has preferable earnings & valuation, BMRA or BRNS?

Which has more risk & volatility, BMRA or BRNS?

Do analysts rate BMRA or BRNS?

Is BMRA or BRNS more profitable?

Do insiders and institutionals believe in BMRA or BRNS?

Summary

How does Biomerica compare to Neuphoria Therapeutics?

Which has more risk and volatility, NEUP or BMRA?

Which has stronger valuation & earnings, NEUP or BMRA?

Do institutionals & insiders believe in NEUP or BMRA?

Do analysts rate NEUP or BMRA?

Is NEUP or BMRA more profitable?

Does the media favor NEUP or BMRA?

Summary

How does Biomerica compare to Tempest Therapeutics?

Which has stronger valuation and earnings, TPST or BMRA?

Does the media prefer TPST or BMRA?

Is TPST or BMRA more profitable?

Do insiders & institutionals hold more shares of TPST or BMRA?

Which has more volatility & risk, TPST or BMRA?

Do analysts recommend TPST or BMRA?

Summary

How does Biomerica compare to Sensei Biotherapeutics?

Is SNSE or BMRA more profitable?

Which has more volatility & risk, SNSE or BMRA?

Do institutionals and insiders hold more shares of SNSE or BMRA?

Does the media prefer SNSE or BMRA?

Do analysts rate SNSE or BMRA?

Which has better valuation & earnings, SNSE or BMRA?

Summary

How does Biomerica compare to Kyntra Bio?

Which has higher earnings and valuation, BMRA or KYNB?

Does the media refer more to BMRA or KYNB?

Is BMRA or KYNB more profitable?

Do insiders and institutionals hold more shares of BMRA or KYNB?

Do analysts recommend BMRA or KYNB?

Which has more risk & volatility, BMRA or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRA vs. The Competition

Biomerica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools